Browsing Category
63786 posts
Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting
– Fixed-dose combination of ASC36 and ASC35 (ASC36_35 FDC) demonstrated superior weight…